Featured Image
Why is it important?
Rosuvastatin 20 mg/day in septic patients increased number ABPSPD, decreased time to initial ABPSPD, norepinephrine dose and duration, with no significant elevation in transaminases or CPK.
Perspectives
The current study has potential limitations though placebocontrolled study in septic patients, lacked comparison with other statins, and measurement of rosuvastatin level and further study is warranted comparing other statins with different doses to evaluate the safe vasopressor effect of statins in septic patients as well as measurement of statin level
Dr Hanaa Abd Allah El Gendy
Ain Shams University
Read the Original
This page is a summary of: Safety and vasopressor effect of rosuvastatin in septic patients, Egyptian Journal of Anaesthesia, July 2014, Elsevier,
DOI: 10.1016/j.egja.2014.02.005.
You can read the full text:
Contributors
The following have contributed to this page
